SEMINARS IN OPHTHALMOLOGY, vol.36, no.8, pp.794-799, 2021 (SCI-Expanded, Scopus)
Aim: Nivolumab is an immune checkpoint inhibitor that has recently been widely used for metastatic malignant melanoma. We report a case who developed multiple different ocular immune-related side effects (iRAEs) related to nivolumab.